1. Balster RL (1991) Discriminative stimulus properties of phencyclidine and other NMDA antagonists. In: Glennon RA, Järbe TUC, Frankenheim J (eds) Drug discrimination: Applications to drug abuse research, National Institute on Drug Abuse Research Monograph Series 116, DHHS Publication No.(ADM) 92-1878. U.S. Government Printing Office, Washington DC, pp 163–180
2. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E (1995) Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6:577–589
3. Baron BM, Harrison BL, McDonald IA, Meldrum BS, Palfreyman MG, Salituro FG, Siegel BW, Slone AL, Turner JP, White HS (1992) Potent indole- and quinoline-containing N-methyl-d-aspartate antagonists acting at the strychnine-insensitive glycine binding site. J Pharmacol Exp Ther 262:947–956
4. Baron BM, Harrison BL, Kehne JH, Schmidt CJ, van Giersbergen PL, White HS, Siegel BW, Senyah Y, McCloskey TC, Fadayel GM, Taylor VL, Murawsky MK, Nyce P, Salituro FG (1997) Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist. Eur J Pharmacol 323:181–192
5. Beardsley PM, Ratti E, Balster RL, Willetts J, Trist D (2002) The selective glycine antagonist gavestinel lacks phencyclidine-like behavioral effects. Behav Pharmacol 13:583–592